Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Kalaris Therapeutics (KLRS) Shares Outstanding (Weighted Average) (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Shares Outstanding (Weighted Average) data on record, last reported at $15.2 million in Q3 2020.

  • For Q3 2020, Shares Outstanding (Weighted Average) rose 1275.79% year-over-year to $15.2 million; the TTM value through Sep 2020 reached $15.2 million, up 1275.79%, while the annual FY2019 figure was $1.3 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $15.2 million in Q3 2020 per KLRS's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $15.2 million in Q3 2020 and bottomed at $921995.0 in Q2 2019.